Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$7.92
▲ $0.06 (+0.8%)
Market data updated: 09/15 03:24 PM
Fundamentals updated: 09/15/2026
News analyzed: 09/15/2026
Market Cap
$542.41M
Day Range
$7.76 - $7.93
52-Week Range
$3.15 - $8.98
Beta
—
Next Earnings
02.11.2026
SOPH is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+149.8% (1Y)
Strengths: 12/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
DCF Fair Value
Estimated fair value: -$11.63 vs. price $7.92 (-246.8%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
53
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
48
Quality
58
Value
38
Momentum
63
Risk
48
Sentiment
92
Fundamental
35
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **SOPHiA GENETICS SA** has centered on its **strong Q2 2026 financial performance**, including record revenue growth and an updated earnings guidance, which boosted investor sentiment. The company also gained attention for **strategic partnerships**, notably a deal with **AstraZeneca** to expand oncology diagnostics, enhancing patient access. Analysts from firms like **HC Wainwright & Co. and BTIG** maintained a **Buy rating** while raising their price targets, reflecting optimism about its growth trajectory.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about SOPHiA GENETICS SA. News trend score: 92. Reason: 7 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
43
🎯 Conviction (vs. Emotion)
41
Psychology
50
Fundamentals
35
Technical
63
Valuation
38
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+51%
Market Narrative
49
Fundamental Reality
41
Narrative Gap
+8
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests **herding** is dominant, as SOPH’s decline (-2.5%) mirrors peer movements (-1.9%), implying passive alignment rather than independent action. Elevated volume (1.21x) and positive sentiment (86/100) hint at cautious FOMO, but the lack of extreme volatility (0.97x ATR) rules out panic. The narrative gap (15 points) may reflect optimism about fundamentals despite weak momentum, consistent with euphoric overvaluation (+44.2% above 200-day average). The key question: *Is the herding driven by rational peer comparison or fading conviction?*
Updated: 09/07/2026, 07:29 PM
What could change this?
👥 What the crowd believes
"SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics (Medical Device Network)"
"HC Wainwright raises price target from $12 to $14 (Benzinga)"
"Record Revenue Growth and ... (GuruFocus.com)"
"Stock sees modest fair value lift after Q2 guidance raise (Simply Wall St.)"
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 77/100
🔴 Weakest match
Benjamin Graham — 19/100
🗣️ Why do they disagree?
The stark divide in verdicts for SOPH reflects a clash between cautious, defensive strategies and more opportunistic or cyclical approaches. Defensive investors like Benjamin Graham and Howard Marks—who prioritize valuation safety and risk mitigation—score this stock very low, flagging it as statistically cheap only under loose standards or outright unsuitable due to perceived risk. In contrast, mid-tier methodologies like Jesse Livermore’s trend-following or Philip Fisher’s quality assessment lean toward neutrality or mild interest, suggesting the stock lacks either a clear upward momentum or exceptional fundamentals. Meanwhile, cyclical or volatility-sensitive models (e.g., Marks’ late-cycle warning or Housel’s volatility concern) paint it as a speculative bet, while behavioral economists like Mackay or Veblen dismiss it outright as a crowd-driven or growth-chasing trap. The consensus leans toward skepticism, with only a handful of approaches tolerating it as a neutral or mid-cycle play.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 77
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 58
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 56
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 47
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 46
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 43
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 39
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 37
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 36
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 36
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 31
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 21
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 19
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 277 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (6 bullish · 4 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
67.4%
Operating Margin
-91.8%
Net Margin
-102.2%
EBITDA Margin
—
ROE
-167.6%
ROA
-48.5%
ROIC
—
EPS
-$1.17
Cash
$70.29M
Total Debt
$47.73M
Current Ratio
1.96
Debt/Equity
1.34
How is Fair Value calculated? →
Current Price
$7.92
Estimated Fair Value (DCF)
-$11.63
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-246.8%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
18.1%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 18.1% | $-43.06M | $-39.50M |
| 2 | 14.2% | $-49.16M | $-41.38M |
| 3 | 10.3% | $-54.21M | $-41.86M |
| 4 | 6.4% | $-57.68M | $-40.86M |
| 5 | 2.5% | $-59.12M | $-38.42M |
Base FCF (last actual year)
$-36.47M
Terminal Value
$-932.27M
Present Value of Terminal Value
$-605.91M
Enterprise Value
$-807.93M
Net Debt
$-22.56M
Equity Value
$-785.38M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$0.69
Tangible Book Value per Share (Tangible NAV)
$0.30
Sentiment based on basic keywords (not AI) — 7 positive, 13 neutral, 0 negative out of the last 20 articles.
Yahoo · 4.9.2026
Simply Wall St. · 4.9.2026
MarketBeat · 27.8.2026
SeekingAlpha · 18.8.2026
Motley Fool · 11.8.2026
Simply Wall St. · 8.8.2026
SeekingAlpha · 5.8.2026
Medical Device Network · 5.8.2026
Benzinga · 5.8.2026
Benzinga · 5.8.2026
GuruFocus.com · 4.8.2026
MarketBeat · 4.8.2026
SeekingAlpha · 4.8.2026
Stocktwits · 4.8.2026
MT Newswires · 4.8.2026
ChartMill · 4.8.2026
PR Newswire · 4.8.2026
PR Newswire · 4.8.2026
CNW Group · 4.8.2026
Benzinga · 4.8.2026
SOPHiA GENETICS SA (SOPH) currently has a StockIQ AI score of 53/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
SOPH currently scores 53/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, SOPH's estimated fair value is -$11.63, which is 246.8% below the current price of $7.92. This is one valuation model among several signals in the fair-value category, not a price target.
SOPH's technical score is 63/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time; Current ratio: 1.96; Price is above the 50-day average.
Based on the real signals StockIQ computed: Estimated fair value: -$11.63 vs. price $7.92 (-246.8%); Operating margin: -91.8% (negative); Net margin: -102.2% (negative).
StockIQ has no recorded dividend payment history for SOPH.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 21 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Xu Zhenyu | Open Market Sale | 27.8.2026 | 556,887 | -10,000 | $8.91 |
| Xu Zhenyu | Open Market Sale | 27.8.2026 | 10,000 | -10,000 | $8.91 |
| HIBBS KATHY L | Open Market Sale | 25.8.2026 | 103,242 | -6,250 | $8.68 |
| Menu Philippe | Open Market Sale | 25.8.2026 | 213,387 | -5,000 | $8.68 |
| Menu Philippe | Open Market Sale | 25.8.2026 | 5,000 | -5,000 | $8.68 |
| HIBBS KATHY L | Open Market Sale | 25.8.2026 | 6,250 | -6,250 | $8.68 |
| Verma Abhimanyu | Open Market Sale | 24.8.2026 | 172,171 | -5,000 | $8.80 |
| Verma Abhimanyu | Open Market Sale | 24.8.2026 | 5,000 | -5,000 | $8.80 |
| Xu Zhenyu | Open Market Sale | 21.8.2026 | 5,408 | -5,408 | $8.40 |
| Xu Zhenyu | Open Market Sale | 20.8.2026 | 4,592 | -4,592 | $8.41 |
| Verma Abhimanyu | Open Market Sale | 19.8.2026 | 177,171 | -5,000 | $8.20 |
| Verma Abhimanyu | Open Market Sale | 19.8.2026 | 5,000 | -5,000 | $8.20 |
| Valente Manuela | Exercise of Derivative Securities | 19.8.2026 | 10,000 | +10,000 | $3.20 |
| Valente Manuela | Open Market Sale | 19.8.2026 | 10,000 | -10,000 | $7.94 |
| Xu Zhenyu | Open Market Sale | 19.8.2026 | 10,000 | -10,000 | $7.94 |
| Valente Manuela | Exercise of Derivative Securities | 19.8.2026 | 10,000 | -10,000 | — |
| Xu Zhenyu | Open Market Sale | 13.8.2026 | 586,887 | -4,000 | $7.52 |
| Xu Zhenyu | Open Market Sale | 13.8.2026 | 4,000 | -4,000 | $7.52 |
| Menu Philippe | Open Market Sale | 12.8.2026 | 218,387 | -5,000 | $7.52 |
| Menu Philippe | Open Market Sale | 12.8.2026 | 5,000 | -5,000 | $7.52 |
| Camblong Jurgi | Open Market Sale | 10.8.2026 | 3,444,322 | -8,500 | $7.61 |
| Camblong Jurgi | Open Market Sale | 10.8.2026 | 8,500 | -8,500 | $7.61 |
| Xu Zhenyu | Exercise of Derivative Securities | 7.8.2026 | 607,887 | +7,000 | $3.28 |
| Xu Zhenyu | Exercise of Derivative Securities | 7.8.2026 | 0 | -7,000 | $3.28 |
| Xu Zhenyu | Open Market Sale | 7.8.2026 | 590,887 | -10,000 | $7.48 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,103,130 shares short as of 2026-08-31 · vs. 768,289 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
45.9% of trading volume this week was short selling, vs. 29.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology